NXTC – Nextcure Inc
NextCure, Inc.NXTC
$1.35Name : NextCure, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $37,767,332.00
EPSttm : -2.19
NextCure, Inc.
$1.35
3.05%$0.04Fair Value
Margin Of Safety %
Put/Call OI Ratio
Float Short %
0.31
EPS 1 Diff
0.19
EPS Year Diff
0.38
Ticker: NXTC
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2024-09-06 | NXTC | 1.42 | 0.09 | 0.00 | 185 |
| 2024-09-09 | NXTC | 1.4 | 0.09 | 0.00 | 185 |
| 2024-09-10 | NXTC | 1.3 | 0.09 | 0.00 | 185 |
| 2024-09-11 | NXTC | 1.32 | 0.09 | 0.00 | 185 |
| 2024-09-12 | NXTC | 1.38 | 0.09 | 0.00 | 185 |
| 2024-09-13 | NXTC | 1.4 | 0.09 | 0.00 | 185 |
| 2024-09-16 | NXTC | 1.29 | 0.09 | 0.00 | 185 |
| 2024-09-17 | NXTC | 1.39 | N/A | N/A | 0 |
| 2024-09-18 | NXTC | 1.39 | N/A | N/A | 0 |
| 2024-09-19 | NXTC | 1.436 | N/A | N/A | 0 |
| 2024-09-20 | NXTC | 1.38 | N/A | N/A | 0 |
| 2024-09-23 | NXTC | 1.4 | 0.00 | 0.00 | 18 |
| 2024-09-24 | NXTC | 1.36 | 0.00 | 0.00 | 18 |
| 2024-09-25 | NXTC | 1.36 | 0.00 | 0.00 | 18 |
| 2024-09-26 | NXTC | 1.41 | 0.00 | 0.00 | 18 |
| 2024-09-27 | NXTC | 1.36 | 0.00 | 0.00 | 18 |
| 2024-09-30 | NXTC | 1.36 | 0.00 | 0.00 | 18 |
| 2024-10-01 | NXTC | 1.3 | 0.00 | 0.00 | 19 |
| 2024-10-02 | NXTC | 1.33 | 0.00 | 0.00 | 19 |
| 2024-10-03 | NXTC | 1.34 | 0.00 | 0.00 | 19 |
| 2024-10-04 | NXTC | 1.32 | 0.00 | 0.00 | 19 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2024-09-06 | NXTC | 1.39 | 33.3 | - | -1.87 |
| 2024-09-09 | NXTC | 1.39 | 33.3 | - | -1.87 |
| 2024-09-10 | NXTC | 1.35 | 33.3 | - | -1.87 |
| 2024-09-11 | NXTC | 1.34 | 33.3 | - | -1.87 |
| 2024-09-12 | NXTC | 1.40 | 33.3 | - | -1.87 |
| 2024-09-13 | NXTC | 1.43 | 33.3 | - | -1.87 |
| 2024-09-16 | NXTC | 1.33 | 33.3 | - | -1.87 |
| 2024-09-17 | NXTC | 1.38 | 33.3 | - | -1.87 |
| 2024-09-18 | NXTC | 1.39 | 33.3 | - | -1.87 |
| 2024-09-19 | NXTC | 1.40 | 33.3 | - | -1.87 |
| 2024-09-20 | NXTC | 1.37 | 33.3 | - | -1.87 |
| 2024-09-23 | NXTC | 1.40 | 33.3 | - | -1.87 |
| 2024-09-24 | NXTC | 1.40 | 33.3 | - | -1.87 |
| 2024-09-25 | NXTC | 1.38 | 33.3 | - | -1.87 |
| 2024-09-26 | NXTC | 1.41 | 33.3 | - | -1.87 |
| 2024-09-27 | NXTC | 1.38 | 33.3 | - | -1.87 |
| 2024-09-30 | NXTC | 1.37 | 33.3 | - | -1.87 |
| 2024-10-01 | NXTC | 1.33 | 33.3 | - | -1.87 |
| 2024-10-02 | NXTC | 1.37 | 33.3 | - | -1.87 |
| 2024-10-03 | NXTC | 1.34 | 33.3 | - | -1.87 |
| 2024-10-04 | NXTC | 1.34 | 33.3 | - | -1.87 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2024-09-06 | NXTC | 0.00 | 4.91 | 0.37 |
| 2024-09-09 | NXTC | 0.00 | 4.91 | 0.37 |
| 2024-09-10 | NXTC | 0.00 | 4.91 | 0.37 |
| 2024-09-11 | NXTC | 0.00 | 4.91 | 0.37 |
| 2024-09-12 | NXTC | 0.00 | 4.91 | 0.36 |
| 2024-09-13 | NXTC | 0.00 | 4.91 | 0.36 |
| 2024-09-16 | NXTC | 0.00 | 4.91 | 0.36 |
| 2024-09-17 | NXTC | 0.00 | 4.91 | 0.36 |
| 2024-09-18 | NXTC | 0.00 | 4.91 | 0.36 |
| 2024-09-19 | NXTC | 0.00 | 4.91 | 0.36 |
| 2024-09-20 | NXTC | 0.00 | 4.91 | 0.36 |
| 2024-09-23 | NXTC | 0.00 | 4.91 | 0.36 |
| 2024-09-24 | NXTC | 0.00 | 4.91 | 0.36 |
| 2024-09-25 | NXTC | 0.00 | 4.91 | 0.30 |
| 2024-09-26 | NXTC | 0.00 | 4.91 | 0.31 |
| 2024-09-27 | NXTC | 0.00 | 4.91 | 0.31 |
| 2024-09-30 | NXTC | 0.00 | 4.91 | 0.31 |
| 2024-10-01 | NXTC | 0.00 | 4.91 | 0.31 |
| 2024-10-02 | NXTC | 0.00 | 4.91 | 0.31 |
| 2024-10-03 | NXTC | 0.00 | 4.91 | 0.31 |
| 2024-10-04 | NXTC | 0.00 | 4.91 | 0.31 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.55
Avg. EPS Est. Current Quarter
-0.34
Avg. EPS Est. Next Quarter
-0.36
Insider Transactions
Institutional Transactions
4.91
Beta
0.79
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value (Academic)
Quality Score
5
Growth Score
19
Sentiment Score
55
Actual DrawDown %
98.8
Max Drawdown 5-Year %
-98.9
Target Price
3.5
P/E
Forward P/E
PEG
P/S
P/B
0.44
P/Free Cash Flow
EPS
-2.2
Average EPS Est. Cur. Y
-1.87
EPS Next Y. (Est.)
-1.56
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.83
Return on Equity vs Sector %
-93.3
Return on Equity vs Industry %
-114.5
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
NextCure, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 82
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
stock quote shares NXTC – Nextcure Inc Stock Price stock today
news today NXTC – Nextcure Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch NXTC – Nextcure Inc yahoo finance google finance
stock history NXTC – Nextcure Inc invest stock market
stock prices NXTC premarket after hours
ticker NXTC fair value insiders trading